Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4

NCT06246513 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT06246513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06246513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 15, 2024
Completion date
November 30, 2029
Enrollment
17 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

limb-girdle muscular dystrophy